Contractions but not AICAR increase FABPpm content in rat muscle sarcolemma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Jeppesen J;Jeppesen J; Albers P; Luiken JJ; Glatz JF; Kiens B
  • Source:
    Molecular and cellular biochemistry [Mol Cell Biochem] 2009 Jun; Vol. 326 (1-2), pp. 45-53. Date of Electronic Publication: 2009 Jan 14.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Springer Country of Publication: Netherlands NLM ID: 0364456 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-4919 (Electronic) Linking ISSN: 03008177 NLM ISO Abbreviation: Mol Cell Biochem Subsets: MEDLINE
    • Publication Information:
      Publication: New York : Springer
      Original Publication: The Hague, Dr. W. Junk B. V. Publishers.
    • Subject Terms:
      Aminoimidazole Carboxamide/*analogs & derivatives ; Fatty Acid-Binding Proteins/*metabolism ; Muscle Contraction/*physiology ; Ribonucleotides/*pharmacology ; Sarcolemma/*metabolism; AMP-Activated Protein Kinases/metabolism ; Aminoimidazole Carboxamide/pharmacology ; Animals ; CD36 Antigens/metabolism ; Glucose Transporter Type 4/metabolism ; Glycogen/metabolism ; Male ; Mitogen-Activated Protein Kinase 1/metabolism ; Mitogen-Activated Protein Kinase 3/metabolism ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/metabolism ; Phosphorylation ; Rats
    • Abstract:
      Unlabelled: In the present study, it was investigated whether acute muscle contractions in rat skeletal muscle increased the protein content of FABPpm in the plasma membrane. Furthermore, the effect of AICAR stimulation on FAT/CD36 and FABPpm protein content in sarcolemma of rat skeletal muscle was evaluated.
      Methods: Male wistar rats (150 g) were anesthetized and either subjected to in situ electrically induced contractions (hindlimb muscles: 20 min, 10-20 V, 200 ms trains, 100 Hz) or stimulated with the pharmacological activator of AMPK, AICAR. To investigate changes in the content of FABPpm and FAT/CD36 in the plasma membrane by these stimuli, the giant sarcolemma vesicle (GSV) technique was applied. The hindlimb muscles were removed and used for the production of GSV and lysates. All samples were analyzed using the western blotting technique.
      Results: Electrical stimulation of rat hindlimb muscle resulted in an increase in FABPpm protein content in the GSV of 61% (P < 0.05) and in FAT/CD36 protein content in the GSV of 33% (P < 0.05). AICAR stimulation increased FAT/CD36 protein content in GSV by 22% (P < 0.05), whereas FABPpm protein content in GSV was unaffected by AICAR treatment. There was no change in total FAT/CD36 and FABPpm protein expression, measured in lysates with western blotting, by either stimulus. AMPK thr172 and ERK1/2 thr202/204 phosphorylation were significantly increased with muscle contractions (P < 0.05), whereas only AMPK thr172 phosphorylation was increased with AICAR stimulation (P < 0.05).
      Conclusion: These data show that contractions increase both FAT/CD36 and FABPpm protein content in skeletal muscle plasma membrane, whereas only FAT/CD36 protein content is increased when muscle are stimulated with AICAR. This suggests that AMPK is involved in regulation of FAT/CD36, but not FABPpm in skeletal muscle. However, since both ERK1/2 thr202/204 and AMPK thr172 phosphorylation are increased during muscle contractions, the present study cannot rule out that both could play a significant role in regulation of FAT/CD36 and FABPpm during muscle contractions.
    • References:
      J Physiol. 2006 Jul 1;574(Pt 1):17-31. (PMID: 16690705)
      Acta Physiol Scand. 2005 Jun;184(2):131-9. (PMID: 15916673)
      Diabetes. 2002 Feb;51(2):284-92. (PMID: 11812734)
      J Physiol. 2007 Jul 1;582(Pt 1):393-405. (PMID: 17478525)
      Mol Interv. 2003 Dec;3(8):445-64. (PMID: 14993453)
      Diabetes. 2004 Dec;53(12):3074-81. (PMID: 15561936)
      Biochem Biophys Res Commun. 2007 Mar 30;355(1):204-10. (PMID: 17292863)
      Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1740-9. (PMID: 17264223)
      Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E133-42. (PMID: 15383373)
      Am J Physiol. 1997 Dec;273(6):E1107-12. (PMID: 9435525)
      J Biol Chem. 2000 May 12;275(19):14501-8. (PMID: 10799533)
      Anal Biochem. 1985 Oct;150(1):76-85. (PMID: 3843705)
      J Appl Physiol (1985). 1999 Jul;87(1):285-93. (PMID: 10409586)
      Mol Cell. 2001 May;7(5):1085-94. (PMID: 11389854)
      Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E813-22. (PMID: 12488245)
      J Appl Physiol (1985). 2004 Oct;97(4):1209-18. (PMID: 15155715)
      Am J Physiol. 1996 Feb;270(2 Pt 1):E299-304. (PMID: 8779952)
      FEBS Lett. 2005 Apr 25;579(11):2428-32. (PMID: 15848183)
      Diabetes. 2004 Jun;53(6):1429-35. (PMID: 15161745)
      Physiology (Bethesda). 2005 Aug;20:260-70. (PMID: 16024514)
      Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E1042-9. (PMID: 15140757)
      J Biol Chem. 1997 May 16;272(20):13255-61. (PMID: 9148944)
      Mol Cell Biochem. 1997 Jan;166(1-2):153-8. (PMID: 9046032)
      J Appl Physiol (1985). 1997 Oct;83(4):1104-9. (PMID: 9338417)
      Exerc Sport Sci Rev. 1998;26:117-32. (PMID: 9696987)
      Am J Physiol. 1993 Feb;264(2 Pt 1):E270-8. (PMID: 8447394)
      J Biol Chem. 1999 Sep 17;274(38):26761-6. (PMID: 10480880)
      J Biol Chem. 2002 Jun 28;277(26):23554-62. (PMID: 11978788)
      Am J Physiol Endocrinol Metab. 2002 Feb;282(2):E435-47. (PMID: 11788377)
      Am J Physiol. 1997 Oct;273(4):E688-94. (PMID: 9357796)
      FEBS Lett. 1987 Jun 15;217(2):232-6. (PMID: 3595854)
      Physiol Genomics. 2004 Mar 12;17(1):31-7. (PMID: 14694205)
      J Biol Chem. 1999 Jul 2;274(27):19055-62. (PMID: 10383407)
      Am J Physiol. 1996 Jan;270(1 Pt 1):E197-201. (PMID: 8772493)
      Am J Physiol. 1999 Oct;277(4):E724-32. (PMID: 10516133)
      Am J Physiol. 1997 Feb;272(2 Pt 1):E262-6. (PMID: 9124333)
      Diabetes. 2003 Jul;52(7):1627-34. (PMID: 12829625)
      Biochem Biophys Res Commun. 2002 Nov 1;298(3):309-16. (PMID: 12413941)
      Biochem Biophys Res Commun. 1997 Feb 13;231(2):463-5. (PMID: 9070301)
      J Biol Chem. 2000 Jan 14;275(2):1457-62. (PMID: 10625698)
    • Accession Number:
      0 (CD36 Antigens)
      0 (Fatty Acid-Binding Proteins)
      0 (Glucose Transporter Type 4)
      0 (Got2 protein, rat)
      0 (Ribonucleotides)
      0 (Slc2a4 protein, rat)
      360-97-4 (Aminoimidazole Carboxamide)
      9005-79-2 (Glycogen)
      EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
      EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
      EC 2.7.11.31 (AMP-Activated Protein Kinases)
      F0X88YW0YK (AICA ribonucleotide)
    • Publication Date:
      Date Created: 20090115 Date Completed: 20090908 Latest Revision: 20211020
    • Publication Date:
      20240829
    • Accession Number:
      10.1007/s11010-008-0006-0
    • Accession Number:
      19142713